Objective To explore the safety evaluation of Bivaludine for patients with high perioperative bleeding risk un-dergoing percutaneous coronary intervention(PCI).Methods Sixty high bleeding risk patients who underwent PCI treatment at the General Hospital of Pingxiang Mining Group Co.from March 2020 to February 2021 and were treated with Heparin Sodium anticoagulation during the perioperative period were selected as the control group.Sixty high bleeding risk patients who underwent PCI treatment from March 2021 to February 2022 were selected as the observation group and treated with Bivaludine anticoagulation.Follow up for 12 months,observe the incidence of postoperative cardiovascular adverse events(MACE),bleeding events,levels of myocardial injury related indicators,and perioperative activated clotting time(ACT)in both groups of patients.Results During the follow-up period of 12 months,the total incidence of MACE in observation group was lower than that in control group,with statistical significance(P＜0.05).The total incidence of bleeding events in obser-vation group was lower than that in control group,and the difference was statistically significant(P＜0.05).24 h after opera-tion,the levels of creatine kinase-MB isoenzyme(CK-MB)and cardiac troponin I(cTnI)in the two groups were lower than before operation,and the differences were statistically significant(P＜0.05).There was no significant difference in ACT level between the two groups before medication,5 min after medication,30 min after medication,and 6 h after surgery(P＞0.05).1 h after surgery,the ACT level of the observation group was lower than that of the control group,with statistical significance(P＜0.05).Conclusion The application of Bivaludine in patients with high perioperative bleeding risk during PCI has a similar myocardial protective effect to Heparin,and can reduce the occurrence of MACE and postoperative bleeding events.The anticoagulant effect is more stable and has higher safety.
维普
万方数据
